US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5
Adiponectin-derived active peptide ADP355 exerts anti-inflammatory
CD352 (NTB-A) Antibody, anti-human, REAfinity™
CD352 (NTB-A) Antibody, anti-human, REAfinity™
CD5L is a pleiotropic player in liver fibrosis controlling damage
Investigating fibrosis and inflammation in an ex vivo NASH murine
Frontiers Nanotechnology in Drug Delivery for Liver Fibrosis
CD56 Antibody, anti-human, REAfinity™
In vivo production of CAR-T cells using CD5/LNP-FAPCAR
Frontiers SNS-032 attenuates liver fibrosis by anti-active
GDF15 deficiency exacerbates CCl 4-induced liver fibrosis. (a